Global Drugs for Herpes Labialis (Oral Herpes) Market Growth 2019-2024

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US.

The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%.

Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD.

North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%.

Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.


According to this study, over the next five years the Drugs for Herpes Labialis (Oral Herpes) market will register a 4.9% CAGR in terms of revenue, the global market size will reach US$ 2710 million by 2024, from US$ 2040 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Herpes Labialis (Oral Herpes) business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Herpes Labialis (Oral Herpes) market by product type, application, key manufacturers and key regions and countries.

This study considers the Drugs for Herpes Labialis (Oral Herpes) value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
External Use
Oral
Injection

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Drugs for Herpes Labialis (Oral Herpes) consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Drugs for Herpes Labialis (Oral Herpes) market by identifying its various subsegments.
Focuses on the key global Drugs for Herpes Labialis (Oral Herpes) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Herpes Labialis (Oral Herpes) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for Herpes Labialis (Oral Herpes) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.